Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
-
Systematic administration of ABT amino bromophenyl morpholin
2024-01-11
Systematic administration of ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl) pyrido[2,3-d] pyrimidine), a potent and selective non-nucleoside AK inhibitor, also generates analgesic effects in animal models of pain (Jarvis et al., 2000, Kowaluk et al., 2000, Suzuki et al., 2001), sug
-
The first suggestions that the cleaved intracellular
2024-01-11
The first suggestions that the cleaved intracellular domain of APP, AICD, might transit to the nucleus and hence selectively regulate gene transcription arose from analogies with the Notch receptor signalling system where similar intra-membrane proteolysis occurs [84], [85] and it was later confirme
-
br Conclusion Our study of
2024-01-10
Conclusion Our study of late-life depression provides evidence of genotype-specific associations between depression and ACE methylation, as well as inverse correlations between ACE methylation and cdk9 inhibitor secretion. These findings highlight the potential need to consider methylation level
-
br Introduction The principal pathways of adrenal and gonada
2024-01-10
Introduction The principal pathways of adrenal and gonadal steroidogenesis have been known for over 50 years (reviewed by Miller and Auchus, 2011). Cholesterol is first converted to pregnenolone via three reactions, 20-hydroxylation, 22-hydroxylation and scission of the 20,22 carbon–carbon bond,
-
The LOX hydroxide metabolites are converted
2024-01-10
The 15-LOX hydroxide metabolites are converted to secondary lipid mediators such as lipoxin A4 from 15-HETE and protectin D1/resolvin D1 from 17-HDoHE [45] (Fig. S3). Importantly, all of these secondary lipid mediators have anti-inflammatory and pro-resolving properties [46], [47], [48]. Lipoxin A4
-
Based on the extracellular domain structures we
2024-01-10
Based on the extracellular domain structures, we can infer that the dimer arrangement of GABAB receptor will undergo substantial changes upon receptor activation (Geng et al., 2013). First, agonist-stimulated closure of GABAB1 VFT would cause an upward rotation of its LB2 domain, coupled with an inw
-
No starting dose adjustment is needed for mild or moderate
2024-01-10
No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad
-
To date defining the prognostic impact of molecular drivers
2024-01-10
To date, defining the prognostic impact of molecular drivers of early-stage NSCLC has been challenging due to the relative rarity of these subsets and the redefinition of comparator arms over time as understanding of the molecular drivers of NSCLC evolved. Indeed, use of molecularly heterogeneous co
-
Neural progenitor cells NPCs are self renewing multipotent c
2024-01-10
Neural progenitor cells (NPCs) are self-renewing, multipotent cells that are capable of differentiating into neurons, astrocytes and oligodendrocytes. NPCs are activated in response to a variety of pathological states in neurodegenerative diseases such as Parkinson’s disease and multiple sclerosis,
-
Indanone and its analogues are useful
2024-01-09
1-Indanone and its analogues are useful intermediates for the synthesis of compounds some of which have applications as pharmaceuticals, especially as analgesic and antihypertensive as well as tobacco flavoring agents. Indanones are commonly used as starting agent for the synthesis of ninhydrin whic
-
br Conclusions The present protocol for localizing
2024-01-09
Conclusions The present protocol for localizing or “spotting” the site of action of an antioxidant in a micro-heterogeneous medium is based on the differences in its reactivity vis-à-vis the series of amphiphobic TEMPO derivatives 1a–f. Plots of the relative antioxidant effectiveness of a given A
-
Z-FA-FMK br Acknowledgments br Introduction Angiotensin II A
2024-01-09
Acknowledgments Introduction Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the
-
Although many factors influence the effects of
2024-01-09
Although many factors influence the effects of medications, during recent years it has become evident that genetic factors could explain the differences between individuals in drug response. These differences are due to variants in genes encoding drug targets [8]. The challenge for pharmacogenetics
-
The specific functions of ERs and AR
2024-01-09
The specific functions of ERs and AR underline their crucial roles during different phases of spermatogenesis. Their deregulation could affect numerous downstream targets, thereby, disrupting spermatogenesis and male fertility. Various studies have shown that estrogen-like chemicals in the environme
-
The increased occurrence of ARIA E in APOE
2024-01-09
The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied
15608 records 196/1041 page Previous Next First page 上5页 196197198199200 下5页 Last page